Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the business’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $46.38, for a total transaction of $7,710,675.00. Following the completion of the sale, the chief executive officer directly owned 8,875,033 shares of the company’s stock, valued at approximately $411,624,030.54. This trade represents a 1.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tempus AI Stock Performance

Shares of TEM stock opened at $42.62 on Friday. The stock’s 50-day moving average is $55.11 and its two-hundred day moving average is $69.65. The firm has a market cap of $7.62 billion, a price-to-earnings ratio of -30.23 and a beta of 5.29. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ARK Invest (Cathie Wood) trimmed positions in Meta and Nvidia and added to Tempus, signaling renewed institutional demand and attention that can support liquidity and investor interest. Cathie Wood’s ARK sells Meta and Nvidia stocks, buys Tempus AI
• Positive Sentiment: Tempus announced a collaboration with Daiichi Sankyo focused on ADC clinical development, reinforcing commercial partnerships in oncology that support longer‑term revenue and platform use cases. Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
• Positive Sentiment: Analysts maintain constructive views — Tempus has a consensus “Moderate Buy” rating, which may help underwrite investor confidence after recent volatility. Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Coverage pieces (Zacks/Yahoo) highlight a string of 2026 collaborations and strategic initiatives that expand Tempus’s AI/diagnostics reach; these are generally positive but are longer‑term catalysts rather than immediate earnings drivers. Tempus AI Reinforces Market Position With Collaborations in 2026
• Negative Sentiment: Zacks notes the stock is down materially since the last earnings report (about a 12.9% decline), pointing to investor concern about recent results/forward outlook and heightening short‑term selling pressure. Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: Technical/volatility pressures: the stock is trading below its 50‑ and 200‑day moving averages and has a high beta, which can amplify downside moves while investors reassess fundamentals and partnership monetization timelines.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TEM shares. BTIG Research dropped their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Robert W. Baird initiated coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Canaccord Genuity Group lowered their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Wednesday, March 11th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $78.62.

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its stake in shares of Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares during the period. Global Retirement Partners LLC increased its stake in shares of Tempus AI by 29.5% during the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after acquiring an additional 167 shares during the period. US Bancorp DE increased its stake in shares of Tempus AI by 6.6% during the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after acquiring an additional 176 shares during the period. Legacy Bridge LLC raised its holdings in Tempus AI by 1.6% during the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after purchasing an additional 193 shares in the last quarter. Finally, Truist Financial Corp raised its holdings in Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after purchasing an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.